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Summary
Objective: Much of what is known about the inﬂammatory response in the synovial membrane (SM) of patients with osteoarthritis (OA) comes
from studies of synovial tissues from end-stage disease. In this study, we sought to better characterize the inﬂammatory inﬁltrate in symptom-
atic patients with early signs of knee OA, and to determine how inﬂammatory cell populations relate to the pattern of cytokine and degradative
enzyme production.
Methods: Study populations comprised patients with degenerative meniscal tears and early cartilage thinning undergoing arthroscopic proce-
dures (early OA) and patients undergoing total knee replacement for end-stage OA. Quantitative real-time polymerase chain reaction (PCR)
was used to measure expression of SM cytokines and enzymes implicated in the pathogenesis of inﬂammatory arthritis and OA, as well as cell
lineage-speciﬁc markers. We quantiﬁed synovial ﬂuid (SF) cytokines and enzymes by enzyme-linked immunosorbent assay (ELISA) and SM
cell populations by immunohistochemistry.
Results: We found increased levels of SF interleukin-15 (IL-15) protein in the early knee OA patients when compared to end-stage OA. Both
SF IL-15 protein and numbers of CD8 cells within SM correlated with matrix metalloproteinase-1 (MMP-1) and three levels. TNF-a, IL-6 and
IL-21 were also detectable in the SF of the majority of patients, and IL-15 levels were associated with IL-6 levels.
Conclusion: IL-15 is elevated in early knee OA, suggesting activation of an innate immune response in the SM. The association of IL-15
expression with CD8 transcripts and MMPs implicates this cytokine in OA pathogenesis and as a candidate therapeutic target.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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There is growing interest in deﬁning the role inﬂammation
plays in osteoarthritis (OA), which is often associated with
low-grade synovitis1. Synovitis has been associated with
symptoms and progression of cartilage degeneration2,3. At
the cellular level, inﬁltration of macrophages and perivascu-
lar T and B lymphocytes is observed, and these inﬁltrates
have been demonstrated in both early and advanced disea-
se4e7. However, the stimuli and consequences of this
inﬁltration remain unclear.
Cytokines produced in innate immune responses, such
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1040(TNF-a) and IL-15, are found routinely in rheumatoid arthri-
tis (RA) joint tissues. Blockade of each of these cytokines
has met with therapeutic success in RA patients8e11. Evi-
dence of lymphocytic activation, such as autoantibody and
TH1 cytokine production, and association of the Major His-
tocompatibility Complex (MHC) class II ‘‘shared epitope’’
with aggressive disease suggest that the adaptive immune
response also plays a role12e14. In OA, the cellular constit-
uents of the inﬁltrates are similar to RA, but inﬁltration is
usually less robust15. Synovial ﬂuid (SF) levels of IL-1b,
IL-6 and TNF-a are detectable in some but not all OA pa-
tients, and are generally lower than in inﬂammatory arthri-
tis16. Furthermore, evidence of lymphocyte activation and
MHC association are more variable than in RA, suggesting
inconsistent activation of adaptive immunity17e19. Despite
these differences, inﬂammation is characteristic of many
advanced OA patients but early disease has been insufﬁ-
ciently studied, due to the complexity of deﬁning early OA
and difﬁculty obtaining sufﬁcient tissue for study. As a result,
1041Osteoarthritis and Cartilage Vol. 17, No. 8we know little about inﬂammatory pathways activated early
on, when therapeutic intervention may be most desirable.
We sought to better characterize the synovial inﬂamma-
tory milieu in patients with early signs of OA compared to
end-stage disease. Furthermore, we sought to determine
how inﬂammatory cells and cytokine expression relate to pro-
teolytic enzyme production in knee OA. Expression of T-lym-
phocyte and macrophage lineage markers was examined in
synovial tissue, and cytokine (IL-1b, IL-6, TNF-a, IL-15,
IL-21, and IL-2) and matrix metalloproteinase (MMP-1,
MMP-3, MMP-9, and MMP-13) levels were measured. The
proteases were chosen based on their documented up-reg-
ulation in patients with OA, while the cytokines were chosen
based on their known roles in inﬂammatory arthritis. IL-1b, IL-
6, and TNF-a have been demonstrated in SF or tissue of
some (mainly advanced) OA patients, but levels of com-
mon-g chain cytokines (IL-15, 21 and 2) in the local
synovial environment have not been previously reported.
MethodsPATIENTSEarly knee OA
Given the association between meniscal pathology and progressive car-
tilage damage, we focused on patients presenting for arthroscopic meniscal
repair20e22. Patients (n¼ 19) with degenerative meniscal tears scheduled for
arthroscopic surgery were recruited from the practices of two orthopedic sur-
geons at Hospital for Special Surgery (HSS). Inclusion criteria included age
40, knee pain 3 months, cartilage abnormality and degenerative meniscal
tear documented on pre-operative magnetic resonance imaging (MRI) or by
intra-operative assessment. We excluded patients with KellgreneLawrence
(KeL) grade> 2 on pre-operative knee ﬁlms, a history of traumatic or
sports-related knee injury, inﬂammatory arthritis, previous knee surgery,
and intra-articular corticosteroid or hyaluronan within 3 months of surgery.
End-stage knee OA
Patients with advanced knee OA (n¼ 15) meeting ACR criteria (clini-
calþ radiographic) who were undergoing total knee replacement surgery
were recruited. Patients were required to have pre-operative KeL score
2 and intra-operative evidence of full-thickness chondral loss. Exclusion
criteria and histologic analyses of synovial membrane (SM) from these pa-
tients were reported previously6. Brieﬂy, patients with signiﬁcant comorbid-
ities, avascular necrosis, or inﬂammatory arthropathy were excluded.
The study was approved by the Institutional Review Board at HSS, and
informed consent was obtained from all patients.CLINICAL, RADIOGRAPHIC, AND MRI DATADemographic data were obtained by chart review. Pre-operative knee ﬁlms
were assessed using the KeL score in a blinded fashion by a musculoskeletal
radiologist. Pre-operativeMRI was available for review on eleven early OA pa-
tients, and was analyzed by a single MR radiologist. MR imaging was per-
formed on a 1.5 or 3.0 Tesla imaging system (General Electric Healthcare,
Milwaukee, WI). Fast spin echo images were obtained to assess articular car-
tilage using a previously validated cartilage-sensitive pulse sequence23. Me-
niscal integrity was scored as follows: 0¼ normal, 1¼ intrasubstance
degeneration, 2¼ degenerative/horizontal tear, 3¼ complex tear with radial
component or displaced fragment. Cartilage integrity was evaluated according
to the Modiﬁed Outerbridge scale23.SYNOVIAL TISSUE AND JOINT FLUID SAMPLESSM was obtained from the suprapatellar region, abutting the trochlear car-
tilage. Previous investigation demonstrated lymphocytic perivascular inﬁl-
trates in this location in 58% of end-stage OA patients6; the end-stage
specimens included here represent a randomly sampled subset of these pa-
tients. Tissue specimens were frozen and stored at 70C. SF was obtained
by aspiration just prior to surgical intervention. After centrifugation to remove
cells and debris, aliquots were frozen and stored at 70C.QUANTITATIVE PCR ANALYSISTotal RNA was extracted from homogenized SM using a puriﬁcation kit
(Gentra Systems, Inc., Minneapolis, MN). All RNA was DNAse-treated,
oligo-dT primed, and cDNA synthesized. mRNA levels of cytokines (IL-1b,IL-6, TNF-a, IL-15, IL-21 and IL-2), cell lineage-speciﬁc molecules (CD3d,
CD4, CD8, CD14, and CD68) and metalloproteinases (MMP-1, MMP-3,
MMP-9 and MMP-13) were measured by real-time PCR (RT-PCR) using
speciﬁc primers (sequences available upon request) and iQ Sybr-Green
Supermix (BioRad, Hercules, CA). After normalizing to GAPDH, expression
levels were calculated relative to the mean value for each gene product in
the end-stage OA group.MEASUREMENT OF CYTOKINE, MMP-1 AND MMP-3 LEVELSSF IL-15 and IL-6 levels were measured using R & D systems Quanti-
kine ELISA kits (Minneapolis, MN; lower limit of detection¼ 2 for IL-15
and 0.7 for IL-6). IL-1b, TNFa, IL-2 and IL-21 were measured using Invitro-
gen Biosource ELISA kits (Camarillo, CA; lower limits of detection¼ 0.06,
0.09, 4, and 15 pg/ml, respectively). MMP-1 and MMP-3 levels were mea-
sured using the Amersham Biotrak Activity Assay Systems (GE Healthcare,
Piscataway, NJ). These assays incorporate an activation step to convert pro-
to active MMP and a modiﬁed urokinase detection system to detect total
MMP concentrations24. Omission of the activation step allows detection of
active enzyme only. Limits of detection are 0.1 ng/ml (MMP-1) and
0.25 ng/ml (MMP-3).
To determine whether ELISA results could be false positives from interfer-
ing rheumatoid factor (RF) or other heterotopic antibodies, the IL-15 ELISA
was repeated with additional SF specimens including three of the higher ex-
pressors from the early OA group. Heteroblock, a reagent which blocks
crosslinking from heterotopic antibodies (Omega Biologicals Inc., Bozeman
MT), was added to ELISA plate wells at 500 ng/ml prior to ﬂuid specimens25.IMMUNOHISTOCHEMICAL STAININGAdditional SM was available from seven end-stage and four early knee
OA patients. Six micron sections of parafﬁn-embedded, formalin ﬁxed tissue
were stained using standard immunoperoxidase technique and monoclonal
antibodies (mAbs) against CD3e (clone PS1, T cells), CD8 (clone 1A5,
cytotoxic T cells), and CD68 (clone KP-1, macrophages) (all from Ventana
Inc., Tucson, AZ). Isotype matched irrelevant mAbs were used as controls.
Positively stained cells were quantiﬁed in ﬁelds containing synovial lining
layer with underlying vascularized subintima. Results are expressed as
mean number of positive cells per high power ﬁeld (hpf). To localize cells
expressing the IL-15 receptor a-chain, immunoperoxidase staining with
polyclonal goat-anti-human IL-15 Ra (N-19, Santa Cruz Biotechnology,
Inc) was perfomed.STATISTICAL ANALYSISGiven small sample size and some irregularly distributed variables, non-
parametric tests were applied throughout. The ManneWhitney t-test was
performed to evaluate differences between group medians, and Spearman’s
correlation coefﬁcients were calculated using Prism 5.0 software (GraphPad,
Inc., San Diego, CA). General linear modeling (GLM) was performed using
SAS 9.1 to investigate the inﬂuence of BMI, age, and gender on mRNA
levels (CD8, IL-15, MMP-1 and MMP-3). Only CD8 relative expression
(RE) did not ﬁt a normal distribution (KolmogoroveSmirnov test) but was dis-
tributed exponentially, and so was log-transformed prior to inclusion in GLM.
Protein levels were measured in a subset of patients (due to SF availability),
therefore SF IL-15 and MMP-1 levels were stratiﬁed by gender, BMI (obese/
non-obese) and age (<65/65þ); between group differences were analyzed
by the ManneWhitney test.ResultsPATIENT CHARACTERISTICSDemographic characteristics of all patients are shown in
Table I. Early OA patients tended to be younger (Manne
Whitney P¼ 0.133), more predominantly male (Chi-square
P¼ 0.21), and have lower BMI (ManneWhitney
P¼ 0.144), though these differences were not statistically
signiﬁcant. Of eleven early OA patients with MRI available,
all had at least a grade 2 (ulceration/ﬁbrillation/ﬁssuring of
articular cartilage involving less than 50% thickness) diffuse
cartilage lesion in one or more locations. All meniscal le-
sions were grade 2: eight medial, two lateral, and one bi-
lateral. Review of operative reports from these 11 patients
revealed no signiﬁcant discrepancies in MRI detection
of meniscal tears, and correlation between MRI and
Table I
Characteristics of patients included in the study
Early OA End-stage OA
N 18 15
Median age
(interquartile range)
60.5 (52.5e70) 68.0 (65.5e71.5)
Median BMI
(interquartile range)
27.46 (23.27e33.05) 32.74 (27.79e35.08)
Male/Female 10/9 6/9
Median KeL score
(interquartile range)
1 (0e1) 3 (3e3)
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(Spearman r’s: medial¼ 0.58, lateral¼ 0.71). The eight re-
maining patients without available MRI had chart documen-
tation (outside MRI report and/or operative report) of
degenerative meniscal tear and diffuse cartilage loss or
ﬁbrillation.CELL-SPECIFIC TRANSCRIPT LEVELS IN EARLY VS
END-STAGE OACell-speciﬁc genes were measured in SM, focusing on
T-lymphocyte (CD3d, CD4 and CD8) and macrophage
(CD14, CD68) markers. Levels of these transcripts were
similar in both OA groups (data not shown).RELATIONSHIP BETWEEN CELL NUMBERS AND GENE
EXPRESSION IN SYNOVIUMFig. 1. Immunohistochemical staining of a representative perivascu-
lar lymphoid aggregate in serial synovial sections from an early
knee OA patient. Standard immunoperoxidase technique wasTo determine whether mRNA levels of cell-speciﬁc
markers reﬂected cellular density, immunohistochemical
staining was carried out for CD3, CD8 and CD68. Paraf-
ﬁn-embedded tissue from seven end-stage and four early
knee OA patients were analyzed. Typical staining patterns
using anti-CD3e, anti-CD8, and anti-CD68 mAbs are shown
in Fig. 1. Antibodies against CD3d and CD8 stained cells
with morphological features of lymphocytes. These cells
were mainly in perivascular aggregates. As expected, mac-
rophages were seen in two distributions: within the lining,
and scattered throughout sublining areas and lymphocytic
accumulations. These patterns were similar in both patient
groups, but lymphocytic inﬁltrates were identiﬁed in all
four early OA vs four of seven (57%) end-stage specimens.
There were correlations between mRNA levels of these
markers and numbers of positively stained cells per hpf.
Spearman correlation coefﬁcients were 0.460 for CD3d
mRNA vs number of CD3eþ cells/hpf; 0.636 for CD8
mRNA vs CD8þ cells/hpf; and 0.454 for CD68 mRNA vs
CD68þ cells/hpf. Only the relationship between CD8
mRNA and cell density achieved statistical signiﬁcance
(95% CI: 0.04e0.90, P¼ 0.035). Similarly, a previous report
indicated that RT-PCR analysis of CD8 transcripts reﬂects
cell numbers in peripheral blood26. These results support
use of transcript levels of CD8 as an approximation of
CD8þ lymphocyte abundance in SM when tissue is limiting.used as described in the text. Staining with the (a) anti-CD3e
mAb (b) anti-CD8 mAb and (c) anti-CD68 mAb is shown. Positive
staining appears brown.SYNOVIAL IL-1b, IL-6 AND TNF-a TRANSCRIPT AND PROTEIN
ABUNDANCE IN EARLY AND END-STAGE OA PATIENTSSM transcript levels of IL-1b, IL-6, and TNF-a were ﬁrst
measured using quantitative RT-PCR. Expression levels
of each transcript, relative to the mean of the end-stage
OA group, were similar in end-stage and early OA
(Fig. 2a). SF collected on the day of surgery was available
from 15 early and 10 end-stage OA patients. SF proteinlevels of these cytokines (Fig. 2b) were not signiﬁcantly dif-
ferent in the two patient groups. SF IL-6 levels were most
variable and appeared to trend higher in some of the early
patients (ns). In comparison, TNF-a levels [Fig. 3(b)] were
comparable in all patients, while IL-1b was detectable in
only four end-stage and one early OA specimen.
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Fig. 3. IL-15, IL-21 and IL-2 levels in the SM and SF of patients with
early (-) and end-stage knee OA (C). (a) mRNA levels (expressed
as in Fig. 2) of IL-15 and IL-2were similar in early and end-stage knee
OA patients, while IL-21 transcript levels were signiﬁcantly higher in
the end-stage knee OA patients. (c) IL-15 protein levels in SF were
signiﬁcantly higher in early OA than in end-stage disease
(P< 0.001), but ﬂuid levels of L-21 and IL-2 were not. IL-2 was
only detectable by ELISA in 4 end-stage patients.
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Fig. 2. IL-1b, IL-6 and TNF-a levels in the SM and SF of patients
with early (-) and end-stage knee OA (C). Transcript levels in
SM were measured by qRT-PCR and expressed relative to the
mean value in the end-stage OA patients (Relative expression¼ 1).
(a) IL-1b, IL-6 and TNF-a transcript levels in SM and (b) SF protein
levels did not differ signiﬁcantly between early and end-stage knee
OA patients, although SF IL-6 levels trended higher in the early
patients (ManneWhitney P¼ ns).
1043Osteoarthritis and Cartilage Vol. 17, No. 8IL-15 TRANSCRIPT AND PROTEIN LEVELS IN OA SM AND SFTable IISynovial transcript and protein levels of IL-15 were exam-
ined next. Transcript levels were comparable in the two
groups, but SF protein levels were signiﬁcantly higher in
early OA patients [Fig. 3(a and b) , left panels] and were de-
tectable in all early and most end-stage patients (9/10).
Levels of IL-15 protein in end-stage patients were consis-
tent with one previous report comparing active RA to a small
number of end-stage OA controls, but no reports in early
disease patients were found27. The IL-15 ELISA was re-
peated in ﬁve specimens, in the presence of Heteroblock
to eliminate interference from RF. Minimal effect on results
was observed (Table II).
A signiﬁcant relationship between CD8 and IL-15 tran-
script levels in the combined OA patients was found (Spear-
man’s r¼ 0.415, 95% CI: 0.02e0.70) which was observed
when analyzing the early OA patient group alone
(r¼ 0.508, 0.01e0.80). This relationship is consistent with
the known role of IL-15 in recruitment and survival of
CD8þ lymphocytes.Measurement of SF IL-15 (pg/ml) in the presence or absence of RF
blockade
Specimen þBlockade Blockade D pg/ml % Difference*
OTHER COMMON-g CHAIN CYTOKINES IN THE SYNOVIAL
ENVIRONMENTOFPATIENTSWITHEARLYANDEND-STAGEOA578 (early) 26.6 28.0 1.4 5.0
581 (early) 14.8 15.9 1.1 6.6
602 (early) 19.1 18.5 0.6 3.20
3 (end-stage) 17.3 17.5 0.2 1.1
654 (end-stage) 11.1 10.7 0.4 3.7
*% Difference¼ change in concentration with addition of Hetero-
block/concentration measured without Heteroblock 100.Given the IL-15 ﬁndings, we decided to measure two
other common-g chain cytokines, IL-21 and IL-2. IL-21 rel-
ative mRNA levels were statistically higher in SM from the
end-stage patients [Fig. 3(a), middle panel], but differences
were not seen in protein levels [Fig. 3(b)]. SM IL-2 mRNA
was detectable in over half of patients, but protein was
only detectable in SF from four end-stage patients.RELATIONSHIPS BETWEEN IL-15 AND OTHER SYNOVIAL
CYTOKINESAn association between IL-15 and IL-6 mRNA (Spearman
r¼ 0.38, 95% CI: 0.001e0.669) and protein levels (Spear-
man r¼ 0.58, 0.20e0.80) was observed. IL-15 mRNA
levels correlated with both TNF (Spearman r¼ 0.51,
0.09e0.77) and IL-21 (Spearman r¼ 0.41, 0.03e0.69) tran-
script levels, but not protein.LOCALIZATION OF IL-15 RECEPTOR a-CHAIN IN SYNOVIUMBoth secretion and recognition of IL-15 is dependent on
expression of the a-chain (IL-15 Ra) of the trimeric IL-15 re-
ceptor28. We performed immunocytochemical staining for
IL-15 Ra, to localize the potential cellular sources and tar-
gets of IL-15 in SM. Figure 4 depicts results in three repre-
sentative end-stage OA patients. IL-15 Raþ cells were
primarily observed in the synovial lining layer and
endothelium.
1044 C. R. Scanzello et al.: Synovial IL-15 levels in early and late OAMMP-1, -3, -9 AND -13 TRANSCRIPT ABUNDANCE IN SYNOVIAL
TISSUE FROM EARLY AND END-STAGE OATo investigate whether synovial expression of MMPs
implicated in OA pathogenesis were related to synovial in-
ﬂammation, we measured a panel of MMP genes. MMP-1
(interstitial collagenase), MMP-3 (stromelysin), MMP-9
(gelatinase), and MMP-13 (collagenase-3) have all been
implicated in cartilage matrix remodeling. Levels of enzyme
transcripts were similar in end-stage and early OA SM (data
not shown). Univariate analyses of enzyme and cell-speciﬁc
gene expression in SM of all OA patients revealed positive
associations between CD3d and MMP-1 and -3, and CD68
and MMP-3 transcripts (Table III). Similar correlation coefﬁ-
cients were obtained when analyzing the patient groups
separately.
The trend seen between CD8 mRNA with MMP-3 tran-
script levels (Table III) was conﬁrmed after quantiﬁcation
of cellular inﬁltration by immunohistochemical staining.
Numbers of CD8þ cells were associated with both MMP-
1 (r¼ 0.70, P¼ 0.016) and MMP-3 (r¼ 0.77, P¼ 0.005)
transcript levels (Fig. 5).MEASUREMENT OF MMP-1 AND -3 IN SFProduction of active MMP proteins is dependent on post-
translational processes such as proteolytic activation and
inhibitor production. Therefore, levels of both total and ac-
tive MMP-1 and MMP-3 were measured in SF from early
OA patients (see Methods). We found statistically signiﬁ-
cant (P< 0.05) associations between levels of SM mRNA
and both total (MMP-1 r¼ 0.718, MMP-3 r¼ 0.790) and
active (MMP-1 r¼ 0.909, MMP-3 r¼ 0.650) SF enzymes.Fig. 4. Immunohistochemical localization of IL-15 Ra in representative pa
different patients were stained using standard immunoperoxidase techniq
Biotechnology, Inc), and counter-stained with methyl green. Positive stain
arrow), endothelium (block arrow) and in scattered cells within the su
(d): Negative control: non-speciﬁc goat-IgG was appRELATIONSHIP BETWEEN SF LEVELS OF IL-15 AND MMP-1
AND -3 EXPRESSION IN SYNOVIAL TISSUETo explore a potential functional role for IL-15, we inves-
tigated whether SF IL-15 protein levels measured in pa-
tients with early (n¼ 11) and end-stage (n¼ 10) OA were
associated with synovial MMP transcripts or protein levels.
A relationship was identiﬁed between IL-15 and total MMP-
1 and -3 levels at the mRNA [Fig 6 (a and b), earlyþ end-
stage patients] and protein level [Fig 6 (c and d), mostly
early OA patients due to limiting quantity of ﬂuid]. SF IL-
15 also correlated with levels of active MMP-1 (r¼ 0.576,
P¼ 0.025).INFLUENCE OF GENDER, BMI AND AGEAs known risk factors for OA were not equally distributed
among the two patient groups, (Table I), we ran generalized
linear models to control for these variables. CD8 (log-trans-
formed), IL-15, MMP-1 and MMP-3 mRNA levels were all
independent of age, gender, and BMI (data not shown). In
addition, we analyzed SF IL-15 and MMP-1 protein levels
after stratifying on gender, BMI (obese vs non-obese) and
age (<65 vs 65þ). There were no signiﬁcant differences
identiﬁed based on these risk factors, whether analyzing
the early and end-stage groups separately or combined.Discussion
Most studies of synovial inﬂammation in OA patients fo-
cus on end-stage disease and utilize ACR criteria for diag-
nosis29. However, these criteria may not be ideal for
identifying patients with earlier stage disease as they largelytients with end-stage knee OA. (aec): SM thin sections from three
ue with the polyclonal goat-anti-human IL-15 Ra (N-19, Santa Cruz
ing appears brown, and was seen primarily in the lining cells (thin
bintima and perivascular mononuclear aggregates (panel a, #).
lied in place of the speciﬁc primary antibody.
Table III
Relationships between cell-specific genes and MMP transcript levels (RE) in the synovium of OA patients (earlyþ end-stage)
MMP-1 RE MMP-3 RE MMP-9 RE MMP-13 RE
CD3d RE r[ 0.431* (0.079e0.687) r[ 0.471 (0.122e0.716) r¼ 0.072 (0.300e0.425) r¼0.210 (0.537e0.174)
CD8 RE r¼ 0.253 (0.152e0.585) r¼ 0.362 (0.042e0.664) r¼ 0.176 (0.230e0.529) r¼0.376 (0.309e0.466)
CD68 RE r¼ 0.273 (0.115e0.589) r[ 0.390 (0.016e0.668) r¼0.292 (0.602e0.095) r¼ 0.066 (0.326e0.438)
*All r values represent Spearman correlation coefﬁcients (95% CI in brackets). Bolded values were statistically signiﬁcant (P < 0.05).
1045Osteoarthritis and Cartilage Vol. 17, No. 8exclude patients under 50 years of age, at which point os-
teophytosis on radiographs or bony overgrowth exam may
already be present. More importantly, these criteria exclude
patients with any joint warmth, effectively eliminating pa-
tients with clinical signs of inﬂammation. Therefore we
sought to deﬁne a symptomatic patient population with early
signs of cartilage degeneration in whom we could study the
inﬂammatory response. We recruited patients with degener-
ative meniscal tears presenting for arthroscopy, who had
documented diffuse cartilage abnormality.
Degenerative menisci can be detected quite commonly in
an aging population, and their contribution to OA incidence
and progression has been documented more recently. Two
independent groups have demonstrated that MRI deﬁned
meniscal degeneration in patients with pre-existing OA is
associated with progressive cartilage loss, and is associ-
ated with development of incident OA in a community pop-
ulation30e32. All early OA patients included in our current
study had documented degenerative meniscal tears. The
trajectory of this population needs to be deﬁned prospec-
tively, but this group is at risk for progression of OA despite
not yet meeting current ACR criteria.
The most interesting and novel ﬁnding in this report is that
levels of IL-15 were increased in early knee OA compared
with end-stage patients [Fig. 3(b)]. IL-15 levels in SF were
signiﬁcantly higher in early OA patients, and were detect-
able in all early patients. This is the ﬁrst report of SF IL-15
levels in a well-deﬁned knee OA population at any disease
stage. A recent case-control study lends support to our ﬁnd-
ings33. Utilizing a proteomic approach to serum biomarker
discovery, IL-15 was one of four serum proteins found to
be associated with both established disease and new de-
velopment of knee and hand OA. Although patients in our
study were not matched for known OA risk factors, SF IL-
15 levels appeared independent of age, gender or BMI.
IL-15 elevation in the early OA group points to a potential
role for innate immune system activation in the r=0.70 (95 % CI 0.15 to 0.92)
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Fig. 5. Relationship between protease expression and CD8þ cells in syno
in the text (n¼ 11, four early and seven end-stage OA). Numbers of inﬁltra
script levels (RE) wipathogenesis of OA. IL-15 is induced in response to activa-
tion of Toll like receptor (TLR)- 434. Its presence in the SF of
these patients suggests innate stimuli within the joint at an
early stage of disease. However, IL-15 often acts as a mem-
brane bound mediator. Soluble cytokine detectable in these
patients may be produced in excess and not bound by avail-
able membrane receptors, or there may be soluble forms
speciﬁc to the synovial environment.
IL-15 shares many activities with IL-2, which we only de-
tected in four of the end-stage SF specimens. In contrast to
IL-2, IL-15 is not primarily a product of activated lympho-
cytes. Instead, it is produced by many cell types including
ﬁbroblasts, phagocytes, dendritic cells, skeletal muscle
and bone marrow stromal cells (reviewed in35). This makes
it an attractive candidate for early immunostimulatory
events within the synovium. Also in contrast to IL-2, IL-15
preferentially recruits and activates the NK cell and
CD8þT-lymphocyte subset and supports the survival of
CD8þ memory cells36e38. Although the speciﬁc impact of
IL-15 on disease pathogenesis remains to be tested, our
additional observations implicate its activity within OA joints.
We found a positive association between IL-15 and CD8
transcript levels suggesting that IL-15 may contribute to re-
cruitment or survival of CD8 lymphocytes within the joint in
OA patients consistent with the known role of IL-15. Alterna-
tively, these gene products may share common transcrip-
tional regulation or cellular sources. We also observed
a signiﬁcant association between SF IL-15 and IL-6 protein
levels. Of interest, these two cytokines together can inﬂu-
ence NK cell activities in tumor environments, IL-15 directly
and IL-6 indirectly through counteraction of TGF-bmediated
inhibition39. In the knee, the signiﬁcance of the IL-15/IL-6
association is unclear, but likely represents a common cel-
lular source for these two cytokines. Both cytokines can be
produced by synovial ﬁbroblasts, macrophages, and poten-
tially adipocytes as well, abundant cell types in the knee
joint40,41.r=0.77 (95% CI 0.31 to 0.92)
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Fig. 6. Relationship between SF IL-15 and MMP-1/3 levels in patients with knee OA. SF levels of IL-15, MMP-1 (n¼ 15, 11 early and four end-
stage OA) and MMP-3 (n¼ 10, all early OA) were measured by ELISA. SF IL-15 pg/ml correlated with (a) MMP-1 and (b) MMP-3 RE levels. In
addition, SF IL-15 levels were associated with (c) total SF MMP-1 and (d) total SF MMP-3 protein levels. r¼ spearman correlation coefﬁcients
(95% conﬁdence interval). In panel (d), p value is reported rather than conﬁdence interval given smaller number of measurements.
Early OA (-), end-stage knee OA (C).
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blasts and other cells in vitro, speciﬁcally MMP-9 and MMP-
142,43. In our patients, we observed associations between SF
IL-15 protein levels, and bothMMP-1 andMMP-3 expression
(Fig. 6). These observations suggest a potential contribution
of IL-15 to generation of mediators of matrix remodeling
in this disease. We have demonstrated expression of IL-15
receptor a-chain in synovial lining cells and endothelium
(Fig. 4) in OA patients; other groups have localized MMP-1
and -3 to these areas of the OA SM as well44,45.
MMP-3 may reﬂect the pattern of synovial inﬂammation in
RA, and is being investigated as a prognostic biomarker in
OA46,47. The association we observed between MMP-3 and
CD8þ lymphocytes suggests that this enzyme may reﬂect
levels of inﬂammation even in OA patients. Although CD8
cells can produce MMPs in vitro, it is unlikely that numbers
of these cells within synovial tissue are sufﬁcient to produce
the high levels of these enzymes seen in the ﬂuid48. In-
stead, it is more likely that lymphocytes act indirectly via ef-
fects on ﬁbroblasts or macrophages to induce enzyme
production49,50.
Like IL-15, other cytokines measured in this study (IL-1b,
IL-6 and TNF-a) can be induced by TLR stimulation51. How-
ever, only IL-15 levels were differentially expressed in early
and end-stage OA patients, suggesting that this cytokine, its
stimuli, or its downstream targets may be potential candi-
dates for molecular biomarkers of early disease develop-
ment. Longitudinal studies are warranted to evaluate the
utility of SF IL-15 in this capacity.
There are reports of T-lymphocyte activation marker ex-
pression in SM of end-stage OA patients17, but it is stillcontroversial whether these cells contribute substantially
to the inﬂammatory response in OA. We measured two
other common-g chain cytokines in this study which are
products of activated T-lymphocyte subsets, namely IL-21
and IL-2. Substantial levels of IL-21 protein were detectable
in both early and end-stage patients, arguing that these lym-
phocytic populations are activated. IL-21, like IL-15, can act
on CD8þ and NK cells, but also has effects on B-cell mat-
uration52. Clearly, further work is necessary to conﬁrm the
cellular source and speciﬁc role that this lymphocyte prod-
uct plays in the synovial reaction.
There are limitations inherent to this study. In particular,
our early OA patient population does not ﬁt currently ac-
cepted criteria for diagnosis of kneeOA. But given limitations
of the accepted criteria, these patients were chosen based
on presence of early cartilage damage, symptoms, and in-
creased risk for progressive OA. Despite similar enzyme
and cell-speciﬁc mRNA levels in the early and end-stage pa-
tients, we can’t rule out differences in SF enzyme levels or tis-
sue cellular inﬁltration densities in the two patient groups as
SF and tissue quantities were limited. For instance, CD8
mRNA levels were similar in early and end-stage patients,
but specimens with the highest numbers of inﬁltrating
CD8þ cells were all from the early group (Fig. 5). And al-
though CD8 transcript levels approximated cellular inﬁltra-
tion in our analysis, this was evaluated in a small subset of
specimens. Finally, this cross-sectional study cannot impli-
cate IL-15 or inﬂammation in disease progression. However,
future longitudinal studies can now be planned to document
disease evolution and deﬁne the role of IL-15. The develop-
ment of effective therapies to prevent OA progression has
1047Osteoarthritis and Cartilage Vol. 17, No. 8been hindered by our inability to adequately deﬁne this prev-
alent joint disease at an early stage, so description of an ap-
propriate patient population is important. The novel ﬁnding of
increased IL-15 levels in this patient group provides further
evidence of activation of innate immunity within SM. Future
work may delineate molecular pathways responsible for
IL-15 production in early OA. And given the central role that
IL-15 plays as an early mediator of immune responses, this
cytokine or its downstream mediators may represent future
targets of therapy in early OA.
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